BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schirò G, Iacono S, Ragonese P, Aridon P, Salemi G, Balistreri CR. A Brief Overview on BDNF-Trk Pathway in the Nervous System: A Potential Biomarker or Possible Target in Treatment of Multiple Sclerosis? Front Neurol 2022;13:917527. [DOI: 10.3389/fneur.2022.917527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Steffen F, Uphaus T, Ripfel N, Fleischer V, Schraad M, Gonzalez-Escamilla G, Engel S, Groppa S, Zipp F, Bittner S. Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort. Neurol Neuroimmunol Neuroinflamm 2023;10. [PMID: 36411080 DOI: 10.1212/NXI.0000000000200055] [Reference Citation Analysis]
2 Kapoor T, Mehan S, Suri M, Sharma N, Kumar N, Narula AS, Alshammari A, Alasmari AF, Alharbi M, Assiri MA, Kalfin R. Forskolin, an Adenylcyclase/cAMP/CREB Signaling Activator Restoring Myelin-Associated Oligodendrocyte Destruction in Experimental Ethidium Bromide Model of Multiple Sclerosis. Cells 2022;11:2771. [DOI: 10.3390/cells11182771] [Reference Citation Analysis]